ArticleArchives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists2013
Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome.
Article in Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survivorship: cognitive function, version 1.2014.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Guideline
- Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.Journal of cancer survivorship : research and practice · 2026Observational
- Screen-detected cognitive impairment, psychological distress, and quality of life in cancer patients undergoing chemotherapy in Yemen.BMC psychology · 2026Article
- Review
- A Scoping Review on Cognition in Myelodysplastic Syndromes: Advances and Challenges.Medical sciences (Basel, Switzerland) · 2025Article
- Prospective analysis of the attendance behaviour of the participants of a facilitated support group for patients after allogeneic hematopoietic cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Pretreatment Cancer-Related Cognitive Impairment in Hodgkin Lymphoma Patients.Current oncology (Toronto, Ont.) · 2023Article
- Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy.Transplantation and cellular therapy · 2022Article
- Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.Current hematologic malignancy reports · 2021Review
- Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms.The oncologist · 2021Review
- Cognitive functioning of older adults prior to hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2020Article
- Embracing the complexity: Older adults with cancer-related cognitive decline-A Young International Society of Geriatric Oncology position paper.Journal of geriatric oncology · 2020Review
- What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.British journal of haematology · 2016Review
- Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.Bone marrow transplantation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study examined the course of neuropsychological functioning in patients with chronic myelogeous leukemia (n = 91) or myelodysplastic syndrome (n = 15) who underwent standard treatment for their disease or allogeneic hematopoietic stem cell transplantation (HSCT) at baseline, 12 months, and 18 months post-treatment. At baseline, 23% of the participants (n = 75) in the longitudinal sample had Z-scores on at least one of the neuropsychological tests that were <1.4. Participants in the study showed improvement over baseline at the 12 and 18 months assessments. The average Z-scores for the six cognitive domains in the longitudinal data set over the course of the study ranged from -0.89 to 0.59. Significant predictors of change in neuropsychological test scores included age, with older participants showing less improvement over time. Other predictors included baseline cognitive domains (language, memory, and attention), previous cocaine use, disease status, intelligence quotient, and quality of life measures. Findings support previous studies in patients with hematological malignancies who showed cognitive impairments at baseline prior to HSCT. However, there was little evidence for further cognitive decline over the course of 18 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.